Retinal Progenitor Cell Therapy Product for Ocular Disease

Blinding diseases are devastating and costly to manage. Currently no treatments exist for inherited forms of blindness, such as Retinitis Pigmentosa (RP), where onset can begin in early childhood. In patients with RP, there are genetic defects in the light-detecting photoreceptor cells of the retina. Without any treatment options available, RP is severely debilitating to a patient population with many potentially productive years of life ahead of them. Stem cell therapies offer a unique potential to treat diseases such as RP. ReNeuron proposes to translate this potential into a treatment for RP using its own particular retinal stem cell technology. Treatment involves injection of the retinal stem cells close to the photoreceptor cells in the back of the eyes. To make this treatment a reality, ReNeuron aims first to demonstrate that its retinal stem cells are safe and effective in preclinical studies supporting a filing for regulatory approval and then to demonstrate safety and efficacy in humans.